NICE recommends Opdivo for lung cancer

The National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales, has recommended use of Opdivo (nivolumab) for some patients with lung cancer.

This recommendation for funding through the Cancer Drugs Fund applies to some people with advanced non-small cell lung cancer if they have already been treated with chemotherapy. Drug developer Bristol-Myers Squibb agreed to provide the drug, which costs £439 per 40-mg vial, at a significant discount.